An anomaly appeared on the Nasdaq stock exchange yesterday when, per an estimate by data provider Ortex, 99% of the shares in public medical tech company MiniMed Group Inc.’s float were sold-short.
In contrast to buyers, short-sellers borrow stock to sell first, hoping to repay shares at a lower price to close their loan with profit.
Up from 47.6% on September 15 and 77% a week earlier, MiniMed’s short interest skyrocketed to an almost unbelievable high yesterday as short-sellers borrowed and sold almost the entire float, i.e. every share of the company available for public trading on Nasdaq’s exchange.
Ortex specializes in live short interest estimates for publicly traded companies. It updates data daily from securities-lending data, often days ahead of official, twice-monthly exchange reports.
According to its data from securities lenders, shares of MiniMed’s common stock on loan nearly equaled the company’s full float yesterday, with available stock to borrow at just 0.08% of short interest.
Understanding this anomaly begins with another publicly-traded company, Medtronic, which incubated MiniMed.
Indeed, MiniMed used to be Medtronic’s diabetes business before Medtronic spun it off in a March 2026 IPO.
As of September 14, Medtronic still owned 90% of MiniMed and was offering a tax-free exchange of 225.3 million shares of MiniMed’s common stock, MMED, for Medtronic’s common stock, MDT.
Although there are 1.28 billion shares in Medtronic’s float — plenty to allow for that conversion while maintaining orderly trading — MiniMed only has 28.5 million shares in its float.
In other words, Medtronic’s share swap offer is seven times larger than MiniMed’s entire tradable supply.
Source link
